Fighting protein-energy wasting in chronic kidney disease: A challenge of complexity

Journal of Renal Nutrition

Volumn 21, Issue 1, 2011, Pages 2-6

  Guarnieri, Gianfranco ^a   Barazzoni, Rocco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; LEPTIN;

ANIMAL; CHRONIC KIDNEY FAILURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; OBESITY; OXIDATIVE STRESS; PROTEIN CALORIE MALNUTRITION; REVIEW;

ANIMALS; GHRELIN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; LEPTIN; OBESITY; OXIDATIVE STRESS; PROTEIN-ENERGY MALNUTRITION;

EID: 78650691605     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.10.008     Document Type: Review

References (59)

1. Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
2. Kopple J.D. McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr 1997, 65:1544-1557.
3. Guarnieri G.F., Toigo G., Situlin R., et al. Direct biochemical analysis of human muscle tissue in hospital malnutrition. J Parenter Enteral Nutr 1987, 11(Suppl 5):55S-63S.
4. Guarnieri G., Toigo G., Situlin R., et al. Muscle biopsy studies in chronically uremic patients: evidence for malnutrition. Kidney Int Suppl 1983, 16:S187-S193.
5. Johansen K.L., Kaysen G.A., Young B.S., et al. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr 2003, 77:842-846.
6. Pupim L.B., Caglar K., Hakim R.M., et al. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int 2004, 66:2054-2060.
7. Stenvinkel P., Heimburger O., Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004, 19:2181-2183.
8. Mehrotra R., Kopple J.D. Nutritional management of maintenance dialysis patients: why aren't we doing better?. Annu Rev Nutr 2001, 21:343-379.
9. Ikizler T.A., Greene J., Wingard R., et al. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995, 6:1386-1391.
10. Bailey J.L., Wang X., England B.K., et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996, 97:1447-1453.
11. Graham K.A., Reaich D., Channon S.M., et al. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 1997, 8:632-637.
12. Kalantar-Zadeh K., Stenvinkel P., Bross R., et al. Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care 2005, 8:388-396.
13. Li Y.P., Reid M.B. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1165-R1170.
14. Himmelfarb J., Stenvinkel P., Ikizler T.A., et al. The elephant in uremia: oxidant stress as an unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
15. Locatelli F., Canaud B., Eckardt K.U., et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
16. Biolo G., Amoroso A., Savoldi S., et al. Association of interferon-gamma +874A polymorphism with reduced long-term inflammatory response in haemodialysis patients. Nephrol Dial Transplant 2006, 21:1317-1322.
17. Supinski G.S., Callahan L.A. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol 2007, 102:2056-2063.
18. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
19. Valerio A., Cardile A., Cozzi V., et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006, 116:2791-2798.
20. Bonnard C., Durand A., Peyrol S., et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008, 118:789-800.
21. Sandri M., Lin J., Handschin C., et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006, 103:16260-16265.
22. Adey D., Kumar R., McCarthy J.T., et al. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 2000, 278:E219-E225.
23. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
24. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
25. Ramos L.F., Shintani A., Ikizler T.A., et al. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008, 19:593-599.
26. Anderson E.J., Lustig M.E., Boyle K.E., et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009, 119:573-581.
27. Fiaschi E., Campanacci L., Guarnieri G.F. Muscle glucose content and hexokinase activity in patients with chronic uremia. Kidney Int Suppl 1975, 7(suppl 3):341-344.
28. Siew E.D., Ikizler T.A. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008, 161:138-144.
29. Bailey J.L., Zheng B., Hu Z., et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006, 17:1388-1394.
30. Siew E.D., Pupim L.B., Majchrzak K.M., et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71:146-152.
31. Stump C.S., Short K.R., Bigelow M.L., et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 2004, 100:7996-8001.
32. Kurella M., Lo J.C., Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005, 16:2134-2140.
33. Ejerblad E., Fored C.M., Lindblad P., et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006, 17:1695-1702.
34. Wahba I.M., Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007, 2:550-562.
35. Guarnieri G.F., Moracchiello M., Campanacci L. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int 1978, 13(Suppl 8):S26-S30.
36. Ritz E., Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008, 19:1065-1070.
37. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
38. Sethi J.K., Vidal-Puig A.J. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007, 48:1253-1262.
39. Kern P.A., Di Gregorio G.B., Lu T., et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52:1779-1785.
40. Kern P.A., Saghizadeh M., Ong J.M., et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
41. Teta D., Maillard M., Halabi G., et al. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl 2008, 108:S112-S118.
42. Barazzoni R., Bernardi A., Biasia F., et al. Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease-impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol 2007, 293:R47-R54.
43. Cheung W., Yu P.X., Little B.M., et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005, 115:1659-1665.
44. Loffreda S., Yang S.Q., Lin H.Z., et al. Leptin regulates proinflammatory immune responses. FASEB J 1998, 12:57-65.
45. Young G.A., Woodrow G., Kendall S., et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition?. Nephrol Dial Transplant 1997, 12:2318-2323.
46. Bossola M., Muscaritoli M., Valenza V., et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin Pract 2004, 97:c76-c82.
47. Stenvinkel P., Lindholm B., Lönnqvist F., et al. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000, 11:1303-1309.
48. Nakazato M., Murakami N., Date Y., et al. A role of ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
49. Wynne K., Giannitsopoulou K., Small C.J., et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005, 16:2111-2118.
50. Barazzoni R., Zanetti M., Stebel M., et al. Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 2003, 124:1188-1192.
51. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
52. Poykko S.M., Kellokoski E., Horkko S., et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
53. Barazzoni R., Zanetti M., Ferreira C., et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92:3935-3940.
54. Barazzoni R., Zanetti M., Stulle M., et al. Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 2008, 27:142-149.
55. Barazzoni R., Zanetti M., Cattin M.R., et al. Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats. Obesity 2007, 15:2614-2623.
56. Barazzoni R., Bosutti A., Stebel M., et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005, 288:E228-E235.
57. Deboer M.D., Zhu X., Levasseur P.R., et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008, 149:827-835.
58. Dixit V.D., Schaffer E.M., Pyle R.S., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004, 114:57-66.
59. Barazzoni R., Zhu X., Deboer M., et al. Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int 2010, 77:23-28.